At diagnosis, the probability of resection after induction (m)FOLFIRINOX for localized PDAC ranged from 7% to 82%, depending on anatomical stage, CA19-9 level, performance status, and tumor size at baseline. This prediction model may help communicating realistic expectations for the probability of resection.

Especially in PDX-PM model, SN38-STPC16 NA reduces PM tumor weight by 80.9%, decreases PM nodule number by 82.3%, and extends median survival by 1.76-fold, outperforming the clinical standard FOLFIRI regimen. Collectively, the transformable SN38-STPC16 NA represents an encouraging delivery platform for effective PM chemotherapy.

P=N/A, N=63, Completed, Washington University School of Medicine | Trial completion date: Apr 2026 --> Jan 2026 | Active, not recruiting --> Completed

In gastric cancer, particularly HER2-negative cStage IV, integrating immune checkpoint inhibitors (ICIs) like nivolumab with chemotherapy presents a promising strategy...The 1-year relapse-free survival and 1-year overall survival were both 100.0% The study underscores the potential of ICI-combined chemotherapy to achieve control of metastatic disease and enable minimally invasive curative surgery in stage IV gastric cancer, thereby offering improved prognosis for this patient cohort. Further research is advocated to confirm long-term survival benefits.

The patient subsequently received first-line treatment with nivolumab plus FOLFOX, achieving a marked radiological response...This case illustrates the potential benefit of immunotherapy in EBV-positive gastric cancer, even in the microsatellite-stable setting. The overlap of biomarkers in this patient may have contributed to immune response, highlighting the importance of comprehensive molecular profiling in GEA and supporting EBV status as a promising predictor of immunotherapy benefit.

The duration of previous chemotherapy, treatment line, and the CAR are useful predictors of PFS in patients with urPC receiving NFF. The proposed nomogram and risk stratification system may facilitate individualized treatment planning and support clinical decision-making.

AFP kinetics provided a rapid and reproducible on-treatment biomarker that complemented imaging. Given the paucity of prospective data in AFP-high gastric cancer, this report is hypothesis-generating and supports further evaluation of chemo-immunotherapy in larger studies.

P2, N=80, Recruiting, Southwest Autism Research & Resource Center | Trial primary completion date: Dec 2025 --> Jul 2026

P2, N=80, Active, not recruiting, Southwest Autism Research & Resource Center | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2025 --> Jul 2026

P2, N=56, Active, not recruiting, Southwest Autism Research & Resource Center | Trial completion date: Dec 2025 --> Jul 2026

The patient remained continent, experienced no postoperative complications or treatment-limiting toxicity, and showed normalization of carcinoembryonic antigen and carbohydrate antigen 19-9 levels. This case provides a carefully contextualized example of transparent surgical reasoning and restrained multidisciplinary management in a rare malignancy with limited prospective evidence.